Introduction
Venous thromboembolism (VTE) comprising deep-vein thrombosis (DVT) and pulmonary embolism (PE) is a common and potentially life-threatening disease, and its recurrences are more frequently observed after unprovoked VTE [1] . It is estimated that after unprovoked VTE a risk of recurrence is about 10% at 1 year and 30% at 5 year [2] . In patients with first unprovoked VTE and low or moderate risk of bleeding extended anticoagulant therapy (no scheduled stop) over a 3-month therapy is recommended, while in patients with high bleeding risk 3 months of anticoagulant treatment is suggested [2] . Anticoagulation treatment is observed to prevent VTE recurrences during its use and is reported to only delay VTE recurrences after anticoagulation withdrawal [3] . However, the majority of real-life patients discontinue the anticoagulation treatment a few months since the VTE event [4] , and prevention of bleeding due to a lifestyle is one of the potential reasons [5] . It has been reported that men have 1.75-higher and patients with elevated D-dimer have 2-fold higher risk of VTE recurrences [2] .
It is suggested that cessation of anticoagulant treatment is safe if the risk of recurrent VTE is less than 5% during a year since the anticoagulation withdrawal [6] . The prediction of recurrent VTE following cessation of anticoagulation still remains challenging. Several strategies regarding anticoagulation withdrawal after the first unprovoked VTE were proposed, as the Vienna Prediction Model, the Dash score or the HERDOO2 rule [7, 8] . The latter rule identifies women at low risk of recurrence (women with maximum two of the following: hyperpigmentation, edema or redness in either leg, increased D-dimer level, obesity and age ≥65 years) in whom anticoagulants can be stopped after 5-7 months since unprovoked VTE event [8] . Rodger et al. observed prospectively that a rate of recurrence was 3% per patient-year (95% confidence interval [CI], 1.8-4.8%) in low-risk women who discontinued anticoagulation and 7.4% (95% CI, 3-15.2%) in high-risk women who stopped taking anticoagulants [9] . D-dimer ≤500 ng/mL and peak thrombin generation <400 nM measured after the cessation of anticoagulation treatment have been also proposed to select patients at low risk of recurrent VTE [2, 8, 10] .
Evidence indicates that formation of more compact clots, relatively resistant to lysis, mediated by both environmental and genetic factors may predispose to VTE [11] in particular unprovoked VTE [12] and may have a prognostic value in VTE prediction [13, 14] . The postthrombotic syndrome (PTS) and associated recurrent VTE has been reported to be associated with prothrombotic plasma clots [15] . To our knowledge, it is unknown whether the HERDOO2 rule is associated with unfavorable plasma clot characteristics and increased thrombin generation. For this reason, we sought to assess the association between the HERDOO2 rule and fibrin clot properties measured 3 months since the DVT event and investigate its impact on VTE recurrences in women after unprovoked VTE.
Patients and methods
We screened 368 consecutive outpatients aged 70 years or younger after first-ever unprovoked VTE who were referred for further clinical evaluation, including the decision of extended anticoagulation therapy (from October 2008 to June 2010). The methodology and patient characteristics have been described in our previous report [13] . We excluded subjects with known malignancy (n=12), chronic kidney disease stage 4 or 5 (n=4), severe thrombophilia, including antiphospholipid syndrome, antithrombin deficiency, homozygous factor V Leiden or prothrombin 20210A mutations (n=24), pregnancy (n=1), international normalized ratio (INR) more than 1.2 (n=2), acute coronary syndrome or ischemic stroke within the previous 3 months (n=2) and acute infection or exacerbated chronic inflammation (n=3) and the other men (n=155) who did not meet the mentioned exclusion criteria and women with VTE provoked by trauma, hospitalization or pregnancy/postpartum (n=55). The current analysis involved women (n=112) with unprovoked and hormone-related VTE. The diagnosis of DVT was confirmed by a positive finding in color duplex sonography and of PE by positive results of high resolution spiral computed tomography. All patients were treated initially with unfractionated or low-molecular-weight heparin (LMWH) at therapeutic doses, then vitamin K antagonists (VKAs) were continued for at least 3 months (hormone-related DVT) or 6 months (unprovoked DVT). Unprovoked VTE was defined as the absence of cancer history, surgery under general anesthesia, major trauma, plaster cast or hospitalization in the last month, pregnancy or delivery in the last 3 months. Hormone-related VTE was defined as VTE associated with oral contraceptive or hormone replacement therapy.
Women were classified into a groups of high (>1 point) or low (<2 points) risk of recurrent VTE based on the HERDOO2 rule, in which single points are given for HER (any Hyperpigmentation, Edema, or Redness in either leg), D-dimer ≥250 µg/L, body mass index (BMI) ≥30 kg/m 2 and age ≥65 years [8, 9] .
The University Bioethical Committee approved the study, and all participants provided informed consent in accordance with the Declaration of Helsinki.
Follow-up
The patients were followed on the 6-month basis (a visit at the center or a telephone contact). The primary endpoint of the study was objectively documented symptomatic recurrent of VTE.
The end of follow-up was defined as the date of a recurrent thromboembolic event or death. The minimal follow-up for patients without recurrent VTE was 30 months. Permeation of plasma fibrin clots in the assay involving addition of tissue factor (TF)
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was assessed using a pressure-driven system and presented as K s , as described previously [16] . A lag phase before the start of fibrin polymerization initiated by adding a Tris buffer containing human thrombin (Sigma) and CaCl 2 to plasma samples, slope of the polymerization curve, along with maximum absorbance at plateau were recorded [12, 17] . Two methods were implemented to assess the efficiency of clot lysis, as described previously [18, 19] . The Calibrated Automated Thrombogram (CAT) was performed (Thrombinoscope, BV, Maastricht, Netherlands) [20] . Briefly, plasma samples was mixed with recombinant relipidated TF and phospholipids. A starting reagent contains CaCl 2 and fluorogenic substrate.
The Fluoroskan Ascent® microplate fluorometer (Thermo Fisher Scientific, Vantaa, Finland) was used to read the fluorescence intensity. The peak thrombin, endogenous thrombin potential (ETP) and the time to thrombin peak were assessed. Thrombophilia screening including Factor V Leiden, prothrombin 20210A, as well as two additional mutations, i.e.
FXIII Val34Leu and α fibrinogen Thr312Ala polymorphisms were performed as described previously [12] .
Statistical analysis
Continuous variables were presented as mean and standard deviation (SD) or median and interquartile range (IQR), categorical and qualitative variables as the number (percentages). The normality of variable distribution was checked by the Shapiro-Wilk test.
Fisher's exact test, Spearman`s rank correlation test, Student's, Welch's t-test and MannWhitney U-test were used as appropriate. The univariable Cox proportional hazards models and logistic regression for risk factors for recurrent VTE were performed and expressed as hazard ratios (HR) or the odds ratio (OR) along with their 95% confidence intervals (CI). The association between prothrombotic phenotype and >1 point in the HERDOO2 rule was analyzed using Chi-square test. The level of significance for the two-sided tests was set below 0.05. All data management and analyses were performed using Statistica 13 (StatSoft Inc., Tulsa, Oklahoma, United States) and package R [21] .
Results
A total of 112 women including 80 women with unprovoked VTE (Table 1 ) and 32
women with hormone-related VTE after first-ever VTE were enrolled into the study. The mean (SD) age of patients was 44.8 (10.8) years.
Both groups did not differ in baseline characteristics except for a higher proportion of DVT combined with PE in unprovoked VTE group (37.5% versus 9.4%, p<0.001). Women with >1 HERDOO2 point were less commonly treated with statins (Table 1) .
Nineteen (23.75%) women had high risk of recurrent VTE and 61 (76.25%) belonged to the low risk group of recurrent VTE. The former group was characterized by 18% higher BMI, 8% higher glucose, 52.8% higher triglycerides, 58.3% higher CRP, 10.7% higher fibrinogen and 15.1% higher D-dimer (Table 1) . Other routine laboratory tests including tPa, PAI-1, peak thrombin and ETP were similar in both groups.
When women with unprovoked VTE and hormone-related VTE were analyzed together the same trends were observed between high and low risk women (n=112, data not shown). (Table 2) .
The HERDOO2 rule and fibrin clot properties

Follow-up
Three women with unprovoked VTE and 1 woman with hormone-related VTE were lost to follow-up. All patients were followed up for median 48.5 (37.5-67) months. The components of the HERDOO2 rule, including postthrombotic syndrome, increased D-dimer, obesity, and older age have been reported to be independent risk factors of recurrent VTE [2, 8, 22] . In previous study we demonstrated that the occurrence of postthrombotic syndrome is associated with lower K s , reduced D-D rate and longer CLT [15] and all these parameters predicted recurrent VTE [13, 15] . This could explain how the HER item could contribute to the association between prothrombotic phenotype and high risk group regarding the HERDOO2 rule. We did not observe HER-related differences in fibrin clot characteristics, however, patients who receive one point for HER tend to have lower K s and longer CLT. It should be added that Rodger et al. found the HER assessed after 5-7 months of oral anticoagulant treatment to be the strongest predictor of recurrent VTE [8] . This observation might refer to older women after unprovoked VTE, while the current study was performed in young and middle-aged females.
In our study obese women after unprovoked VTE were characterized by higher ΔAbs and lower D-D rate , while other fibrin clot features were similar in obese and non-obese subjects. It has been observed that switching obese patients to low-fat diet resulted in longer CLT while with no change in K s [23] . Recently, we reported that both higher ΔAbs and reduced D-D rate were risk factors of recurrent VTE [13] . It has been demonstrated that obese patients had higher concentrations of fibrinogen [24] . This could partially explain why in our study the difference in K s disappeared after adjustment for fibrinogen, a main determinant of clot characteristics [25] , when female patients were divided according to the HERDOO2 rule.
The current study provides additional evidence for prothrombotic alterations in obesity including hypofibrinolysis.
The key finding of the present study is slightly lower K s (-6.8%) and markedly prolonged CLT (+23.8%) observed in high risk women after unprovoked VTE, which supports the concept of an important contribution of the prothrombotic fibrin clot phenotype to a prothrombotic state following VTE. Importantly no evidence of increased thrombin generation using the CAT assay was noted, indicating other mechanism underlying changes in clot structure and function. Reduced D-D rate (-6.8%) that was also observed in high risk women and reflected impaired transport of tPa in fibrin networks and its slower degradation even at higher tPa concentrations confirms that higher scores in the HERDOO2 rule are associated with hypofibrinolysis. A similar abnormality has been reported to predispose to residual vein obstruction [26] which might lead to an increased risk of DVT recurrence.
Patients characterized by combination of risk factors of recurrent VTE could be predisposed to formed more compact plasma fibrin clots associated with impaired susceptibility to lysis. The correlations between D-D rate , CLT and the number of points in the HERDOO2 reported by us could support the notion that the predictive value of the HERDOO2 rule is partially driven by alternations in fibrin clot properties, however whether the same alterations can be seen in elderly women after unprovoked VTE remains to be established. In our cohort women with high scores in the HERDOO2 rule were less commonly treated with statins. It has been reported that statins could improve fibrin clot properties [17, 27] and also the beneficial effect of statins on VTE recurrences has been suggested [28, 29] . We observed faster fibrinolysis in women receiving statins, which supports a role of statins as modifiers of clot properties in patients.
We did not classify hormone-or pregnancy-related VTE as unprovoked in this study, like some researchers did [8, 30] even if the risk of recurrent VTE is increased in women with hormone-related VTE compared with those following VTE provoked by surgery or trauma [30] . We found that women after VTE related to oral contraceptives/hormone replacement therapy did not differ in VTE recurrences compared with women after unprovoked VTE, which is in line with previous studies [31, 32] . However, subjects after VTE related to estrogen use had 29% lower recurrence risk than non-users (adjusted HR 0.71; 95% CI 0.58-0.88) in the study of 4170 women aged 15 to 64 years [33] . Importantly, in women with factor V Leiden mutation discontinuation of oral contraceptives increased K s and shortened CLT [34] .
We observed a lower rate of recurrent VTE in women compared with some previous reports reporting data on older patient populations [35] . Moreover, we failed to find an increased risk of recurrent VTE in women with >1 HERDOO2 point. This observation might result from a few discrepancies between ours and other studies on this issue. Firstly, the number of individuals in our study was limited. We assessed the HERDOO2 after 12-15 weeks of anticoagulant therapy while the HERDOO2 rule was originally calculated after 5-7 months of anticoagulation [9] . Women in the present high risk group were younger than those reported by Rodger et al. (mean age, 44.7 years and 65.5 years, respectively) [9] . The low risk women aged ≥50 years had a higher recurrence rate (5.7/100 patient-years versus 2/100 patient-years) [9] . Moreover, we measured D-dimer concentrations using a different assay from that used in the study by Rodger et al. [9] . We excluded patients with previous provoked VTE, which was not the case in the previous seminal work [9] . Taken together, the current study suggests that the value of the HERDOO2 can be limited among women aged 65 years or less, even if prothrombotic alterations can be detected in blood drawn from patients at high risk of VTE recurrence using this rule. Still, long-term anticoagulation treatment in patients after unprovoked VTE without unacceptable bleeding is recommended, and the HERDOO2 rule is a clinical tool that can help identify younger women in whom long-term anticoagulation would not be beneficial [36] .
Several study limitations merit consideration. The number of study participants was limited and we observed a low incidence rate of recurrent VTE events. Moreover, only patients suspected of VTE recurrence based on signs and symptoms were evaluated by imaging, so asymptomatic VTE events could have been omitted. We determined each variable at a single time point, so changes with time in some of them cannot be excluded. All patients after the first ever VTE ceased VKAs during follow-up. It is unclear whether following anticoagulant treatment with non-vitamin K antagonist oral anticoagulants, instead of heparins and VKAs, as well as statin administration may affect a predictive value of the HERDOO2 rule as well as fibrin clot properties [28, 29, 37] .
In conclusion, we demonstrated that prothrombotic clot phenotype is associated with >1 point in the HERDOO2 rule in female patients after unprovoked VTE. This could provide a possible explanation for a predictive value of this scoring system in women, however, the HERDOO2 rule appears to have a limited usefulness in the prediction of recurrent VTE among middle-aged women. It is tempting to speculate that in this female population assessment of clot density and lysability might be more useful than the HERDOO2 rule.
Large-scale studies are needed to corroborate this hypothesis.
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